Apoptotic cell death and atypical cell death are mutually exclusive
. | DMSO, % . | . | . | zVAD, % . | . | . | Imatinib, % . | . | . | zVAD + imatinib, % . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 3 hours . | 6 hours . | 12 hours . | 3 hours . | 6 hours . | 12 hours . | 3 hours . | 6 hours . | 12 hours . | 3 hours . | 6 hours . | 12 hours . | ||||||||
| Intact | 98.3 ± 0.5 | 98.3 ± 0.5 | 98.4 ± 0.1 | 99.8 ± 0.1 | 99.8 ± 0.1 | 99.6 ± 0.1 | 95.3 ± 0.4 | 94.4 ± 0.6 | 90.6 ± 0.3 | 99.8 ± 0.1 | 97.2 ± 0.4 | 93.3 ± 0.6 | ||||||||
| Apoptotic | 1.8 ± 0.5 | 1.5 ± 0.6 | 1.4 ± 0.1 | < 0.1 | < 0.1 | < 0.1 | 4.8 ± 0.4 | 5.3 ± 0.7 | 8.2 ± 0.5 | < 0.1 | < 0.1 | < 0.1 | ||||||||
| Atypical | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | 2.8 ± 0.3 | 6.6 ± 0.6 | ||||||||
. | DMSO, % . | . | . | zVAD, % . | . | . | Imatinib, % . | . | . | zVAD + imatinib, % . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 3 hours . | 6 hours . | 12 hours . | 3 hours . | 6 hours . | 12 hours . | 3 hours . | 6 hours . | 12 hours . | 3 hours . | 6 hours . | 12 hours . | ||||||||
| Intact | 98.3 ± 0.5 | 98.3 ± 0.5 | 98.4 ± 0.1 | 99.8 ± 0.1 | 99.8 ± 0.1 | 99.6 ± 0.1 | 95.3 ± 0.4 | 94.4 ± 0.6 | 90.6 ± 0.3 | 99.8 ± 0.1 | 97.2 ± 0.4 | 93.3 ± 0.6 | ||||||||
| Apoptotic | 1.8 ± 0.5 | 1.5 ± 0.6 | 1.4 ± 0.1 | < 0.1 | < 0.1 | < 0.1 | 4.8 ± 0.4 | 5.3 ± 0.7 | 8.2 ± 0.5 | < 0.1 | < 0.1 | < 0.1 | ||||||||
| Atypical | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | < 0.1 | 2.8 ± 0.3 | 6.6 ± 0.6 | ||||||||
Quantitative data were obtained from cytospin specimens of BV173 cells treated with the indicated agents for 3, 6, and 12 hours. “Apoptotic cells” are defined by nuclear fragmentation and chromatin condensation, while “atypical cells” are defined by marked cellular pyknosis, round and shrinked morphology, and a lack of nuclear fragmentation. In imatinib-treated cells, the apoptotic cells appeared as early as 3 hours after treatment and increased thereafter. In zVAD + imatinib-treated cells, the atypical cells appeared later at 6 hours. Of note, the atypical cells were absent in imatinib-treated cells, and the apoptotic cells were absent in zVAD + imatinib-treated cells. Values indicate the percentage of each morphologic type. Data represent means ± SEM of 4 individual experiments.